Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B

Organon & Co.

2024-Q3 EPS reported $2.92 revenue$4,811,000,000

GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).
Women's Health +5% as-reported; Nexplanon grew 11% ex-FX; fertility +14% ex-FX.
Biosimilars +16% as-reported; Hadlima launch drove uptake; Renflexis +4% ex-FX.
FY2024 revenue midpoint raised $50M to $6.375-6.425B; Adj. EBITDA margin guide revised to 30-31%.
Established Brands +2% as-reported; flat ex-FX growth expected for full year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.